title: Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose.
abstract: BACKGROUND
  The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY(3-36) and GLP-1(7-36 amide), on glucose homeostasis are unknown.
  
  
  OBJECTIVE
  This study sought to investigate the acute effects of PYY(3-36) and GLP-1(7-36) amide, individually and in combination, on insulin secretion and sensitivity.
  
  
  METHODS
  Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY(3-36) alone, GLP-1(7-36) amide alone, and a combination of PYY(3-36) and GLP-1(7-36) amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility.
  
  
  RESULTS
  PYY(3-36) alone caused a small but nonsignificant increase in AIRg. GLP-1(7-36) amide alone and the combination of PYY(3-36) and GLP-1(7-36) amide did increase AIRg significantly. No significant differences in SI were observed with any intervention.
  
  
  CONCLUSIONS
  PYY(3-36) lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-1(7-36) amide alone and the combination of PYY3-36 and GLP-1(7-36) amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY(3-36) and GLP-1(7-36) amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.
authors.affiliation: Section of Investigative Medicine (T.M.T., V.S., R.C.T., A.A., B.C.T.F., A.D.S., S.M., K.C.R.B., M.D., J.M., M.A.G., S.R.B.), and Department of Endocrinology and Metabolism (I.F.G.), Imperial College London, London W12 0NN, United Kingdom.
authors.forename: Tricia M
authors.initials: TM
authors.lastname: Tan
authors.forename: Victoria
authors.initials: V
authors.lastname: Salem
authors.forename: Rachel C
authors.initials: RC
authors.lastname: Troke
authors.forename: Ali
authors.initials: A
authors.lastname: Alsafi
authors.forename: Benjamin C T
authors.initials: BC
authors.lastname: Field
authors.forename: Akila
authors.initials: A
authors.lastname: De Silva
authors.forename: Shivani
authors.initials: S
authors.lastname: Misra
authors.forename: Kevin C R
authors.initials: KC
authors.lastname: Baynes
authors.forename: Mandy
authors.initials: M
authors.lastname: Donaldson
authors.forename: James
authors.initials: J
authors.lastname: Minnion
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Ghatei
authors.forename: Ian F
authors.initials: IF
authors.lastname: Godsland
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Bloom
mesh_terms: D000328:Adult; D001786:Blood Glucose; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology*; D005947:Glucose / Q000008:administration & dosage*; D005951:Glucose Tolerance Test; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007328:Insulin / Q000097:blood*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D050177:Overweight / Q000097:blood*; D010446:Peptide Fragments / Q000494:pharmacology*; D019894:Peptide YY / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007328:Insulin; D010446:Peptide Fragments; D019894:Peptide YY; C055453:glucagon-like peptide 1 (7-36)amide; C061785:peptide YY (3-36); D052216:Glucagon-Like Peptide 1; D005947:Glucose